About Us

Extraordinary minds.

Extraordinary science.

Ola Ola, heart and kidney transplant recipient, post-transplant lymphoproliferative disease (PTLD) advocate

Natural biology. Groundbreaking approach.

Atara's mission is to unleash the extraordinary power of the body's immune system. By harnessing the compelling biological features of T cells—the immune system's most effective weapon—to target Epstein-Barr virus (EBV), we seek to deliver cell-based innovation in the form of next-generation allogeneic T-cell immunotherapies that aim to change patients' lives worldwide.

Our unique EBV T-cell platform sets us apart.

Our EBV T-cell platform uses allogeneic (donor-derived) T cells, next-generation CAR T technologies, and world-class manufacturing capabilities aimed at harnessing the power of the immune system to target and destroy disease-causing cells. Our platform is unique—and it's what makes Atara well-positioned to deliver on our goal of bringing off-the-shelf immunotherapies to patients in need.

Learn More About Our Technology

Management team

Pascal Touchon

Pascal Touchon

President and Chief Executive Officer

Jakob Dupont, M.D.

Jakob Dupont, M.D.

Head of Global Research & Development

Utpal Koppikar

Utpal Koppikar

Chief Financial Officer

Charlene Banard

Charlene Banard

Chief Technical Officer

Amie Krause

Amie Krause

Chief People Officer

AJ Joshi, M.D.

AJ Joshi, M.D.

Chief Medical Officer

Cokey Nguyen, Ph.D.

Cokey Nguyen, Ph.D.

Chief Scientific Officer

Dan Maziasz

Dan Maziasz

Head of Corporate Strategy and Business Development

Hyonelle Youngson, Pharm.D.

Hyonelle Youngson, Pharm.D.

Head of Business Excellence & Transformation

Jill Henrich

Jill Henrich

Head of Global Regulatory Affairs

K. Amar Murugan

K. Amar Murugan

General Counsel

Board of Directors

Pascal Touchon

Pascal Touchon

President and Chief Executive Officer

Carol G Gallagher, Pharm.D.

Carol G Gallagher, Pharm.D.

Chair of the Board

Ameet Mallik

Ameet Mallik

Director

Eric Dobmeier

Eric Dobmeier

Director

Matthew Fust

Matthew Fust

Director, Audit Committee Chair

William Heiden

William Heiden

Director

Maria Grazia Roncarolo, M.D.

Maria Grazia Roncarolo, M.D.

Director

Beth Seidenberg, M.D.

Beth Seidenberg, M.D.

Director

We innovate with strategic partners.

As a pioneer of allogeneic T-cell immunotherapy, we're furthering our impact by collaborating with the world's leading academic institutions and companies to develop next-generation technologies.

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center

In 2015, Atara entered into a license agreement with the Memorial Sloan Kettering Cancer Center for development, manufacturing, and more.

QIMR Berghofer

QIMR Berghofer

In 2015, we obtained an exclusive license to develop and commercialize immunotherapies utilizing technology developed by Dr. Rajiv Khanna.

Moffitt Cancer Center

Moffitt Cancer Center

In 2018, we entered into an agreement and collaboration with Moffitt Cancer Center to develop T-cell immunotherapies by Dr. Marco Davila.

Pierre Fabre

Pierre Fabre

In 2021, Atara and Pierre Fabre entered a strategic collaboration to commercialize tab-cel® in Europe, Middle East, Africa, and other select markets.

Sustainable, ethical business practices.

We support environmental, social, and governance initiatives. Learn how we align our work with our mission, culture, and core values every day.